Abstract | BACKGROUND: AIM: MATERIAL AND METHODS: Retrospective review of HIV patients with Kaposi sarcoma seen at a public hospital and at a HIV clinic. Detailed description of patients subjected to antiretroviral treatment and chemotherapy. RESULTS: Between 1995 and 2002, 1127 HIV infected patients were seen. Of these, 78 had Kaposi sarcoma, 15 were treated with high activity antiretroviral therapy ( HAART) and 17 with HAART and chemotherapy. These 32 patients were male, and their mean age was 33 +/- 6 years. The initial CD4 count in 27 of these was 95 +/- 105 cells/ml. The initial viral load in 18 of these was 370,246 +/- 768,693 RNA copies/ml. Of the 15 patients treated with HAART, eight had a complete remission, one had a partial response, one remained stationary and five died. Of the 17 patients treated with HAART and chemotherapy, seven had complete remission, five had a partial response, 2 remained stationary and three died. The lapse of complete remission was 272 days for those treated with HAART and 292 days for those treated with HAART and chemotherapy. CONCLUSIONS: In HIV patients with Kaposi sarcoma, high activity antiretroviral therapy, associated or not to chemotherapy, induces complete remission in 46% of patients and partial remission in 16%.
|
Authors | Martín Lasso, Jorge Pérez, Luis Noriega, Andrea Malebrán, Susana Espinoza |
Journal | Revista medica de Chile
(Rev Med Chil)
Vol. 131
Issue 5
Pg. 483-90
(May 2003)
ISSN: 0034-9887 [Print] Chile |
Vernacular Title | Sarcoma de Kaposi y VIH: tratamiento antirretroviral y quimioterapia en 32 pacientes. |
PMID | 12879808
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Anti-HIV Agents
- Reverse Transcriptase Inhibitors
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy, pathology)
- Adult
- Anti-HIV Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Drug Therapy, Combination
- HIV Infections
(complications, mortality)
- Humans
- Male
- Middle Aged
- Retrospective Studies
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Sarcoma, Kaposi
(drug therapy, etiology, radiotherapy)
- Time Factors
- Viral Load
|